News
Article
On November 12, 2021, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft for the treatment of adults with polycythemia vera.
Read the FDA announcement.
Read PharmaEssentia's announcement for more information.
Posted 11/15/2021